ADVERTISEMENT
StartUps and SMEs
The success of AimedBio’s IPO may indicate investors are returning to the South Korean biopharma sector amid a series of large global out-licensing deals by domestic ventures and the strong performance of some recent biotech debutants on Kosdaq.
Private Company Edition: Braveheart Bio licensed its selective cardiac myosin inhibitor from Hengrui. Also, Arena BioWorks shuts down after raising $500m in 2024, GHO Capital closed a €2.5bn ($2.9bn) private equity fund and new cash brings Tubulis’s series C to €344m ($401m).
Corporate venture arms can be powerful growth partners, but founders who don’t take time to understand them risk missing their greatest value.
Strategic partnerships and disciplined spending are emerging as key survival tools in challenging funding environment.
The top awards at the annual MedTech Innovator APAC are handed out to an increasingly varied range of products and applications, and the class of 2025 was no exception in its reflection of healthtech’s ever-widening innovator base.
At recent conferences in Seoul, participants discussed various hurdles for growth in the Korean biotech ecosystem and potential opportunities such as the ongoing collaborations between Korea and Japan.
The billion-dollar startup has doubled headcount, released massive datasets and is advancing therapeutics, but the hard part lies ahead.
Yuhan's R&D president talks to Scrip about the leading Korean pharma firm’s open innovation strategy with Korean bioventures, as well as other strategies crucial for the company to transform into a major global player.
India rolls out amended R&D financial assistance plan targeting certain ‘priority areas’ and calls for proposals from industry and startups. While the corpus is modest, the scheme hopes to enable the ‘Innovate in India’ ecosystem and includes a co-funding provision.
India rolls out amended R&D financial assistance plan targeting certain ‘priority areas’ and calls for proposals from industry and startups. While the corpus is modest, the scheme hopes to enable the ‘Innovate in India’ ecosystem and includes a co-funding provision.
The mathematician-turned-CEO is building an atlas of clinical immune biology to revolutionize precision medicine.
Private Company Edition: Early-stage drug developers saw the biggest drop in venture capital investment in Q2, according to Biomedtracker. Also, Atlas raised a $400m fund to back prior investments, Enveda’s $150m series D round and Harvey Berger will helm Arena BioWorks.